%PDF-1.5
%
2 0 obj
<<
/Lang (tr)
/Type /Catalog
/Pages 4 0 R
/Metadata 5 0 R
/Outlines 6 0 R
>>
endobj
5 0 obj
<<
/Type /Metadata
/Length 2865
/Subtype /XML
>>
stream
2013-06-26T15:55:10+03:00
HP Smart Document Scan Software 2.60
2013-07-18T16:01:37+03:00
OmniPage CSDK 16
application/pdf
endstream
endobj
54 0 obj
<<
/Length 12064
>>
stream
0 0 0 rg
0 0 0 RG
q
1 0 0 1 0 0 cm
595 0 0 837 0 0 cm
/ImagePart_2 Do
Q
BT
0 0 0 rg
0 0 0 RG
1 0 0 1 257.75 702.7 Tm
3 Tr
/OPBaseFont0 11.5 Tf
(KISA RN BILGISI ) Tj
1 0 0 1 87.5 669.25 Tm
99 Tz
(1.) Tj
1 0 0 1 100.45 669.25 Tm
97 Tz
(BE) Tj
1 0 0 1 116.65 669.25 Tm
78 Tz
/OPSUFont0 11.5 Tf
() Tj
1 0 0 1 122.75 669.25 Tm
103 Tz
/OPBaseFont0 11.5 Tf
(ER) Tj
1 0 0 1 139.3 669.25 Tm
57 Tz
/OPSUFont0 11.5 Tf
( ) Tj
1 0 0 1 143.3 669.25 Tm
101 Tz
/OPBaseFont0 11.5 Tf
( TIBBI RNN ADI ) Tj
1 0 0 1 86.75 652.7 Tm
/OPBaseFont1 11.5 Tf
(GOYART 35 mg film kapl) Tj
1 0 0 1 214.199 652.7 Tm
31 Tz
/OPSUFont0 11.5 Tf
( ) Tj
1 0 0 1 216.349 652.7 Tm
101 Tz
/OPBaseFont1 11.5 Tf
( tablet ) Tj
1 0 0 1 86.4 619.2 Tm
99 Tz
/OPBaseFont0 11.5 Tf
(2.) Tj
1 0 0 1 100.45 618.85 Tm
98 Tz
(KAL) Tj
1 0 0 1 126 618.85 Tm
52 Tz
/OPSUFont0 11.5 Tf
() Tj
1 0 0 1 130.699 618.85 Tm
97 Tz
/OPBaseFont0 11.5 Tf
(TAT) Tj
1 0 0 1 154.449 618.85 Tm
57 Tz
/OPSUFont0 11.5 Tf
() Tj
1 0 0 1 159.099 618.85 Tm
101 Tz
/OPBaseFont0 11.5 Tf
(F VE KANT) Tj
1 0 0 1 222.5 618.85 Tm
52 Tz
/OPSUFont0 11.5 Tf
() Tj
1 0 0 1 227.15 618.85 Tm
98 Tz
/OPBaseFont0 11.5 Tf
(TAT) Tj
1 0 0 1 250.9 618.85 Tm
57 Tz
/OPSUFont0 11.5 Tf
() Tj
1 0 0 1 255.599 618.85 Tm
95 Tz
/OPBaseFont0 11.5 Tf
(F B) Tj
1 0 0 1 273.25 618.5 Tm
57 Tz
/OPSUFont0 11.5 Tf
() Tj
1 0 0 1 277.899 618.5 Tm
96 Tz
/OPBaseFont0 11.5 Tf
(LE) Tj
1 0 0 1 293.399 618.5 Tm
75 Tz
/OPSUFont0 11.5 Tf
() Tj
1 0 0 1 304.199 618.5 Tm
96 Tz
/OPBaseFont0 11.5 Tf
(M ) Tj
1 0 0 1 86.4 602.649 Tm
100 Tz
(Etkin madde: ) Tj
1 0 0 1 158.4 602.299 Tm
/OPBaseFont1 11.5 Tf
(Her bir film kapl) Tj
1 0 0 1 237.599 602.299 Tm
31 Tz
/OPSUFont0 11.5 Tf
( ) Tj
1 0 0 1 239.75 602.299 Tm
100 Tz
/OPBaseFont1 11.5 Tf
( tablet; ) Tj
1 0 0 1 86.75 585.7 Tm
(35 mg risedronat sodyum ierir. ) Tj
1 0 0 1 86.4 551.899 Tm
98 Tz
/OPBaseFont0 11.5 Tf
(Yard) Tj
1 0 0 1 112.7 551.899 Tm
36 Tz
/OPSUFont0 11.5 Tf
() Tj
1 0 0 1 115.9 551.899 Tm
98 Tz
/OPBaseFont0 11.5 Tf
(mc) Tj
1 0 0 1 131.05 551.899 Tm
36 Tz
/OPSUFont0 11.5 Tf
( ) Tj
1 0 0 1 133.55 551.5 Tm
99 Tz
/OPBaseFont0 11.5 Tf
( madde: ) Tj
1 0 0 1 86.049 535.299 Tm
101 Tz
/OPBaseFont1 11.5 Tf
(Laktoz monohidrat ) Tj
1 0 0 1 175.699 534.95 Tm
2000 Tz
(\t) Tj
1 0 0 1 206.65 534.95 Tm
98 Tz
(2 mg ) Tj
1 0 0 1 86.049 518.399 Tm
99 Tz
(Yard) Tj
1 0 0 1 109.799 518.399 Tm
31 Tz
/OPSUFont0 11.5 Tf
() Tj
1 0 0 1 112.7 518.399 Tm
99 Tz
/OPBaseFont1 11.5 Tf
(mc) Tj
1 0 0 1 127.799 518.399 Tm
26 Tz
/OPSUFont0 11.5 Tf
( ) Tj
1 0 0 1 129.599 518.399 Tm
103 Tz
/OPBaseFont1 11.5 Tf
( maddeler iin 6.1'e bak) Tj
1 0 0 1 244.449 518.399 Tm
31 Tz
/OPSUFont0 11.5 Tf
() Tj
1 0 0 1 247.3 518.399 Tm
93 Tz
/OPBaseFont1 11.5 Tf
(n) Tj
1 0 0 1 253.8 518.399 Tm
31 Tz
/OPSUFont0 11.5 Tf
() Tj
1 0 0 1 256.699 518.399 Tm
89 Tz
/OPBaseFont1 11.5 Tf
(z. ) Tj
1 0 0 1 86.049 484.899 Tm
99 Tz
/OPBaseFont0 11.5 Tf
(3.) Tj
1 0 0 1 100.099 484.899 Tm
101 Tz
(FARMAST) Tj
1 0 0 1 167.4 484.899 Tm
57 Tz
/OPSUFont0 11.5 Tf
() Tj
1 0 0 1 172.099 484.55 Tm
100 Tz
/OPBaseFont0 11.5 Tf
(K FORM ) Tj
1 0 0 1 86.4 468.35 Tm
/OPBaseFont1 11.5 Tf
(Film kapl) Tj
1 0 0 1 131.75 468.35 Tm
36 Tz
/OPSUFont0 11.5 Tf
( ) Tj
1 0 0 1 134.3 468.35 Tm
102 Tz
/OPBaseFont1 11.5 Tf
( tablet ) Tj
1 0 0 1 86.049 451.449 Tm
101 Tz
(Beyaz, yuvarlak, bikonveks, film kapl) Tj
1 0 0 1 265.3 451.449 Tm
31 Tz
/OPSUFont0 11.5 Tf
( ) Tj
1 0 0 1 267.5 451.1 Tm
101 Tz
/OPBaseFont1 11.5 Tf
( tablet ) Tj
1 0 0 1 86.049 417.949 Tm
99 Tz
/OPBaseFont0 11.5 Tf
(4.) Tj
1 0 0 1 99.7 417.949 Tm
97 Tz
(KL) Tj
1 0 0 1 117 417.949 Tm
57 Tz
/OPSUFont0 11.5 Tf
() Tj
1 0 0 1 121.7 417.949 Tm
91 Tz
/OPBaseFont0 11.5 Tf
(N) Tj
1 0 0 1 130.3 417.6 Tm
52 Tz
/OPSUFont0 11.5 Tf
() Tj
1 0 0 1 134.65 417.6 Tm
101 Tz
/OPBaseFont0 11.5 Tf
(K ZELLIKLER ) Tj
1 0 0 1 86.049 401.399 Tm
95 Tz
(4.1. ) Tj
1 0 0 1 102.599 401.399 Tm
1910 Tz
(\t) Tj
1 0 0 1 121.7 401.05 Tm
100 Tz
(Teraptik endikasyonlar ) Tj
1 0 0 1 86.4 383.75 Tm
99 Tz
/OPBaseFont1 11.5 Tf
() Tj
1 0 0 1 100.099 383.399 Tm
100 Tz
(Postmenopozal osteoporoz ve erkek osteoporozunun tedavisinde endikedir. ) Tj
1 0 0 1 86.049 350.3 Tm
95 Tz
/OPBaseFont0 11.5 Tf
(4.2. ) Tj
1 0 0 1 102.599 349.899 Tm
1870 Tz
(\t) Tj
1 0 0 1 121.299 349.899 Tm
100 Tz
(Pozoloji ve uygulama ) Tj
1 0 0 1 230.75 349.899 Tm
57 Tz
/OPSUFont0 11.5 Tf
() Tj
1 0 0 1 235.449 349.899 Tm
98 Tz
/OPBaseFont0 11.5 Tf
(ekli ) Tj
1 0 0 1 86.049 333.35 Tm
(Pozoloji: ) Tj
1 0 0 1 85.7 317.149 Tm
97 Tz
/OPBaseFont1 11.5 Tf
(Yeti) Tj
1 0 0 1 106.2 317.149 Tm
52 Tz
/OPSUFont0 11.5 Tf
() Tj
1 0 0 1 110.5 316.799 Tm
102 Tz
/OPBaseFont1 11.5 Tf
(kinlerde nerilen doz haftada bir kez al) Tj
1 0 0 1 297.35 316.45 Tm
31 Tz
/OPSUFont0 11.5 Tf
() Tj
1 0 0 1 300.25 316.45 Tm
102 Tz
/OPBaseFont1 11.5 Tf
(nan 35 mg tablettir. Tabletler her hafta ayn) Tj
1 0 0 1 505.449 316.1 Tm
31 Tz
/OPSUFont0 11.5 Tf
( ) Tj
1 0 0 1 507.6 316.1 Tm
105 Tz
/OPBaseFont1 11.5 Tf
( gnde ) Tj
1 0 0 1 85.7 300.25 Tm
90 Tz
(al) Tj
1 0 0 1 94.299 300.25 Tm
31 Tz
/OPSUFont0 11.5 Tf
() Tj
1 0 0 1 97.2 300.25 Tm
100 Tz
/OPBaseFont1 11.5 Tf
(nmal) Tj
1 0 0 1 121.299 300.25 Tm
36 Tz
/OPSUFont0 11.5 Tf
() Tj
1 0 0 1 124.549 300.25 Tm
87 Tz
/OPBaseFont1 11.5 Tf
(d) Tj
1 0 0 1 130.3 300.25 Tm
36 Tz
/OPSUFont0 11.5 Tf
() Tj
1 0 0 1 133.55 300.25 Tm
84 Tz
/OPBaseFont1 11.5 Tf
(r. ) Tj
1 0 0 1 85.7 266.399 Tm
100 Tz
/OPBaseFont0 11.5 Tf
(Uygulama s) Tj
1 0 0 1 145.099 266.399 Tm
31 Tz
/OPSUFont0 11.5 Tf
() Tj
1 0 0 1 148.3 266.399 Tm
93 Tz
/OPBaseFont0 11.5 Tf
(kl) Tj
1 0 0 1 158.05 266.399 Tm
57 Tz
/OPSUFont0 11.5 Tf
( ) Tj
1 0 0 1 169.9 266.399 Tm
98 Tz
/OPBaseFont0 11.5 Tf
( ve sresi: ) Tj
1 0 0 1 85.7 249.85 Tm
100 Tz
/OPBaseFont1 11.5 Tf
(Tablet her hafta ayn) Tj
1 0 0 1 180 249.85 Tm
31 Tz
/OPSUFont0 11.5 Tf
( ) Tj
1 0 0 1 182.15 249.85 Tm
101 Tz
/OPBaseFont1 11.5 Tf
( gnde al) Tj
1 0 0 1 226.449 249.85 Tm
26 Tz
/OPSUFont0 11.5 Tf
() Tj
1 0 0 1 228.949 249.85 Tm
98 Tz
/OPBaseFont1 11.5 Tf
(nmal) Tj
1 0 0 1 253.099 249.85 Tm
26 Tz
/OPSUFont0 11.5 Tf
() Tj
1 0 0 1 255.949 249.85 Tm
87 Tz
/OPBaseFont1 11.5 Tf
(d) Tj
1 0 0 1 262.1 249.85 Tm
26 Tz
/OPSUFont0 11.5 Tf
() Tj
1 0 0 1 264.949 249.85 Tm
84 Tz
/OPBaseFont1 11.5 Tf
(r. ) Tj
1 0 0 1 86.049 232.549 Tm
99 Tz
() Tj
1 0 0 1 99.7 232.2 Tm
102 Tz
(Risedronat sodyumun absorpsiyonu yiyeceklerden ve polivalan katyonlardan etkilenmektedir ) Tj
1 0 0 1 85.7 216 Tm
106 Tz
(\(Bkz. 4.5. Di) Tj
1 0 0 1 150.5 216 Tm
72 Tz
/OPSUFont0 11.5 Tf
() Tj
1 0 0 1 156.25 216 Tm
108 Tz
/OPBaseFont1 11.5 Tf
(er t) Tj
1 0 0 1 173.9 216 Tm
26 Tz
/OPSUFont0 11.5 Tf
() Tj
1 0 0 1 176.75 215.649 Tm
106 Tz
/OPBaseFont1 11.5 Tf
(bbi rnler ile etkile) Tj
1 0 0 1 277.199 215.649 Tm
57 Tz
/OPSUFont0 11.5 Tf
() Tj
1 0 0 1 281.899 215.649 Tm
105 Tz
/OPBaseFont1 11.5 Tf
(imler ve di) Tj
1 0 0 1 335.5 215.299 Tm
73 Tz
/OPSUFont0 11.5 Tf
() Tj
1 0 0 1 341.3 215.299 Tm
104 Tz
/OPBaseFont1 11.5 Tf
(er etkile) Tj
1 0 0 1 381.25 215.299 Tm
57 Tz
/OPSUFont0 11.5 Tf
() Tj
1 0 0 1 385.899 215.299 Tm
95 Tz
/OPBaseFont1 11.5 Tf
(im ) Tj
1 0 0 1 403.199 215.299 Tm
52 Tz
/OPSUFont0 11.5 Tf
() Tj
1 0 0 1 407.5 214.899 Tm
105 Tz
/OPBaseFont1 11.5 Tf
(ekilleri\), bu nedenle yeterli ) Tj
1 0 0 1 85.299 199.45 Tm
102 Tz
(emilimin sa) Tj
1 0 0 1 141.099 199.1 Tm
73 Tz
/OPSUFont0 11.5 Tf
() Tj
1 0 0 1 147.25 199.1 Tm
98 Tz
/OPBaseFont1 11.5 Tf
(lanmas) Tj
1 0 0 1 180.349 199.1 Tm
31 Tz
/OPSUFont0 11.5 Tf
( ) Tj
1 0 0 1 182.5 199.1 Tm
102 Tz
/OPBaseFont1 11.5 Tf
( iin hastalar GOYART 35 mg') Tj
1 0 0 1 331.55 198.7 Tm
36 Tz
/OPSUFont0 11.5 Tf
( ) Tj
1 0 0 1 334.1 198.7 Tm
102 Tz
/OPBaseFont1 11.5 Tf
( kahvalt) Tj
1 0 0 1 372.6 198.7 Tm
31 Tz
/OPSUFont0 11.5 Tf
() Tj
1 0 0 1 375.5 198.35 Tm
101 Tz
/OPBaseFont1 11.5 Tf
(dan nce: ilk yemekten, di) Tj
1 0 0 1 500.399 198.35 Tm
73 Tz
/OPSUFont0 11.5 Tf
() Tj
1 0 0 1 506.149 198.35 Tm
99 Tz
/OPBaseFont1 11.5 Tf
(er t) Tj
1 0 0 1 522 198.35 Tm
31 Tz
/OPSUFont0 11.5 Tf
() Tj
1 0 0 1 525.25 198.35 Tm
95 Tz
/OPBaseFont1 11.5 Tf
(bbi ) Tj
1 0 0 1 85.299 182.5 Tm
102 Tz
(rnlerden veya ieceklerden \(su d) Tj
1 0 0 1 251.65 182.5 Tm
46 Tz
/OPSUFont0 11.5 Tf
() Tj
1 0 0 1 262.449 182.149 Tm
102 Tz
/OPBaseFont1 11.5 Tf
(nda\) 30 dakika nce su ile birlikte almal) Tj
1 0 0 1 453.6 181.799 Tm
31 Tz
/OPSUFont0 11.5 Tf
() Tj
1 0 0 1 456.5 181.799 Tm
93 Tz
/OPBaseFont1 11.5 Tf
(d) Tj
1 0 0 1 462.6 181.799 Tm
31 Tz
/OPSUFont0 11.5 Tf
() Tj
1 0 0 1 465.5 181.799 Tm
102 Tz
/OPBaseFont1 11.5 Tf
(r. GOYART 35 ) Tj
1 0 0 1 85.299 165.95 Tm
114 Tz
(mg yaln) Tj
1 0 0 1 128.9 165.95 Tm
36 Tz
/OPSUFont0 11.5 Tf
() Tj
1 0 0 1 131.75 165.95 Tm
128 Tz
/OPBaseFont1 11.5 Tf
(zca su ile al) Tj
1 0 0 1 203.05 165.6 Tm
31 Tz
/OPSUFont0 11.5 Tf
() Tj
1 0 0 1 205.9 165.6 Tm
98 Tz
/OPBaseFont1 11.5 Tf
(nmal) Tj
1 0 0 1 229.699 165.6 Tm
31 Tz
/OPSUFont0 11.5 Tf
() Tj
1 0 0 1 232.55 165.6 Tm
87 Tz
/OPBaseFont1 11.5 Tf
(d) Tj
1 0 0 1 238.699 165.6 Tm
31 Tz
/OPSUFont0 11.5 Tf
() Tj
1 0 0 1 241.55 165.6 Tm
116 Tz
/OPBaseFont1 11.5 Tf
(r. Baz) Tj
1 0 0 1 274.699 165.6 Tm
31 Tz
/OPSUFont0 11.5 Tf
( ) Tj
1 0 0 1 276.85 165.25 Tm
119 Tz
/OPBaseFont1 11.5 Tf
( maden sular) Tj
1 0 0 1 347.75 165.25 Tm
31 Tz
/OPSUFont0 11.5 Tf
() Tj
1 0 0 1 350.649 165.25 Tm
93 Tz
/OPBaseFont1 11.5 Tf
(n) Tj
1 0 0 1 356.75 165.25 Tm
36 Tz
/OPSUFont0 11.5 Tf
() Tj
1 0 0 1 359.649 164.899 Tm
111 Tz
/OPBaseFont1 11.5 Tf
(n kalsiyum konsantrasyonu yksek ) Tj
1 0 0 1 85.299 149.399 Tm
98 Tz
(oldu) Tj
1 0 0 1 106.2 149.399 Tm
78 Tz
/OPSUFont0 11.5 Tf
() Tj
1 0 0 1 111.95 149.049 Tm
101 Tz
/OPBaseFont1 11.5 Tf
(undan, bunlar) Tj
1 0 0 1 176.75 149.049 Tm
36 Tz
/OPSUFont0 11.5 Tf
() Tj
1 0 0 1 179.65 149.049 Tm
101 Tz
/OPBaseFont1 11.5 Tf
(n kullan) Tj
1 0 0 1 218.15 149.049 Tm
31 Tz
/OPSUFont0 11.5 Tf
() Tj
1 0 0 1 221.4 149.049 Tm
98 Tz
/OPBaseFont1 11.5 Tf
(lmamas) Tj
1 0 0 1 257.75 149.049 Tm
31 Tz
/OPSUFont0 11.5 Tf
( ) Tj
1 0 0 1 259.899 148.7 Tm
101 Tz
/OPBaseFont1 11.5 Tf
( gerekmektedir \(Bkz. 5.2. Farmakokinetik ) Tj
1 0 0 1 85.7 131.75 Tm
99 Tz
() Tj
1 0 0 1 99.349 131.399 Tm
101 Tz
(GOYART 35 mg tableti almay) Tj
1 0 0 1 244.449 131.399 Tm
31 Tz
/OPSUFont0 11.5 Tf
( ) Tj
1 0 0 1 246.599 131.049 Tm
101 Tz
/OPBaseFont1 11.5 Tf
( unutan hastalar, ila almad) Tj
1 0 0 1 375.5 131.049 Tm
36 Tz
/OPSUFont0 11.5 Tf
() Tj
1 0 0 1 378.699 131.049 Tm
98 Tz
/OPBaseFont1 11.5 Tf
(klar) Tj
1 0 0 1 397.1 131.049 Tm
31 Tz
/OPSUFont0 11.5 Tf
() Tj
1 0 0 1 399.949 131.049 Tm
93 Tz
/OPBaseFont1 11.5 Tf
(n) Tj
1 0 0 1 406.1 131.049 Tm
36 Tz
/OPSUFont0 11.5 Tf
( ) Tj
1 0 0 1 408.6 130.7 Tm
101 Tz
/OPBaseFont1 11.5 Tf
( fark ettikleri gn ierisinde ) Tj
1 0 0 1 85.299 114.85 Tm
113 Tz
(bir GOYART 35 mg tablet almal) Tj
1 0 0 1 259.55 114.5 Tm
31 Tz
/OPSUFont0 11.5 Tf
() Tj
1 0 0 1 262.449 114.5 Tm
93 Tz
/OPBaseFont1 11.5 Tf
(d) Tj
1 0 0 1 268.55 114.5 Tm
31 Tz
/OPSUFont0 11.5 Tf
() Tj
1 0 0 1 271.449 114.1 Tm
110 Tz
/OPBaseFont1 11.5 Tf
(rlar. Daha sonra hastalar normal rutinlerine dnerek, ) Tj
1 0 0 1 84.95 97.899 Tm
108 Tz
(tabletleri nceden belirledikleri gne gre almaya devam etmelidirler. ) Tj
1 0 0 1 443.5 97.549 Tm
47 Tz
/OPSUFont0 11.5 Tf
() Tj
1 0 0 1 446.75 97.549 Tm
113 Tz
/OPBaseFont1 11.5 Tf
(ki tablet ayn) Tj
1 0 0 1 512.649 97.2 Tm
26 Tz
/OPSUFont0 11.5 Tf
( ) Tj
1 0 0 1 514.45 97.2 Tm
121 Tz
/OPBaseFont1 11.5 Tf
( gn ) Tj
1 0 0 1 299.899 65.5 Tm
96 Tz
/OPBaseFont0 11.5 Tf
(1 / 13 ) Tj
ET
endstream
endobj
59 0 obj
<<
/Name /ImagePart_2
/Type /XObject
/Width 1653
/Filter [/JBIG2Decode]
/Height 2325
/Length 17833
/Subtype /Image
/ColorSpace /DeviceGray
/BitsPerComponent 1
>>
stream
0 u 8 Aśz㸯OR)v D-܀VA?;H%NuPC@a>FlL3%Da? OH\}=i:~CkܐPٴR]RBW4v0> KDsE]Z5eRn|J(؊{`Jj}C\?mzd (ཛh$B
{6fkp ZDŽ
H0&"`V{Hjt3z{t˸&q"35XAD =?vczb\vdCMvAgν]܈oY
^" hFepݛ/mUnЬw+KmzSab>%m==xwduyf5-ߨN
a0c^m)xcy8o4쇰_CH~tuv\_ؒBy4 ַ|v&̈{d_(9FVp1ξ!`d:4j_˶ءrٞב7o1ڟZkVB*nOdwfqAٔǐ['y'^x5Qrк ʽ/^ګoi%P$%NVoRWv}wWToA}abRU_/ք{q~M3p:˿1)jQXM㛎npK;jvjQ'sPz+9*T$AuC@Ժ-DPVmC-\w?)[:ñ Q{,?كZM1:vW$Z|R>JrCiW1p|.p:ϼNxخL~oyAHHp5کxe
'OgD(&=D6OL${:!oD~ΓT!VW665S9Uzh00XE`+e @oϑҝ=!cݫ8Ɉ0":u@pbќ:huɛh-x"&xGYͬ (#>O֠
Ĕ`F;>U